Retinoic Acid Triggers Cancer-Killing Gene
By Biotechdaily staff writers
Posted on 22 May 2002
A study has found that treatment with retinoic acid, a vitamin A derivative, activates a genetic switch that brings about the death of leukemia cells. The study was reported in the March 19, 2002, issue of the Proceedings of the National Academy of Sciences.Posted on 22 May 2002
Reinoic acid (RA) in used in cancer therapy and causes remissions in acute promyelocytic leukemia (APL), a rare but lethal leukemia. This leukemia is marked by an unusual genetic defect that rearranges the receptor for RA. A hallmark of this retinoid response is the degradation of the abnormal receptor that causes the disease.
While studying the RA pathway, a research team from Dartmouth Medical School (Hanover, NH, USA) found a target gene that appears to mimic the drug action, degrade the abnormal receptor, and induce cell death. When introduced into leukemia cells, this gene, called UBE1L, reproduced key aspects of the retinoic acid response and caused the death of the leukemia cells.
"This is exciting because we have identified a potential pharmacologic target that signals a death program in leukemia and perhaps other cancer cells as well,” said first author Sutisak Kitareewan.
Related Links:
Dartmouth Medical School
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Rapid Sepsis Test
SeptiCyte RAPID
